Boston Medical Sciences Raises ¥5.55B Series B
Boston Medical Sciences raises 5.55 billion yen in a Series B round to advance its medical AI diagnostic technology for colorectal cancer.
Boston Medical Sciences Raises ¥5.55B Series B
Boston Medical Sciences, a Tokyo-based medical technology startup, has raised 5.55 billion yen in a Series B funding round. The company focuses on developing AI-driven medical solutions for the early detection and examination of colorectal cancer.
Investors
The funding round included participation from Japan Growth Capital Investment Corporation, Global Brain Corporation, and Beyond Next Ventures Inc.
Boston Medical Sciences Use of Funds
The capital will be used to accelerate research and development and clinical trials for medical AI in the colorectal cancer field. Additionally, the funds will support regulatory efforts in Japan and the United States, the establishment of commercialization systems within Japan, and the expansion of overseas business operations, particularly in the U.S. market.
About Boston Medical Sciences
Founded in 2023 by physicians with experience at Harvard Medical School and Massachusetts General Hospital, Boston Medical Sciences is dedicated to the mission of preventing deaths from colorectal cancer. The company develops next-generation colon CT examination technology, including its proprietary Laxative-Free Virtual Endoscopy which utilizes AI-powered image analysis.
Funding Details
Company Website: https://b-ms.tech
Company: Boston Medical Sciences
Raised: ¥5.55B
Round: Series B
Funding Date: November 13, 2026
Additional Investors: Japan Growth Capital Investment Corporation, Global Brain Corporation, Beyond Next Ventures Inc.
Software Category: HealthTech
Source: https://prtimes.jp/main/html/rd/p/000000012.000129637.html